Fig. 2From: Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19Time to sustained (≥ 48 h) symptom alleviation through Day 21. Participants who never achieve sustained (≥ 48 h) symptom alleviation (two or more, non-missing, consecutive scored questionnaires that showed symptom alleviation) are censored at day of withdrawal or Day 21, whichever was earliest. IV intravenousBack to article page